S&P 500   3,761.72 (-1.52%)
DOW   30,854.39 (-1.33%)
QQQ   304.08 (-1.64%)
AAPL   120.22 (-1.51%)
MSFT   226.51 (-0.46%)
FB   257.67 (+0.88%)
GOOGL   2,023.20 (+0.59%)
TSLA   610.76 (-6.50%)
AMZN   2,978.01 (-0.90%)
NVDA   495.31 (-3.30%)
BABA   230.98 (-2.24%)
CGC   30.99 (-6.77%)
GE   13.46 (+0.15%)
MU   84.19 (-5.52%)
NIO   38.90 (-6.33%)
AMD   78.13 (-3.38%)
T   28.91 (+0.66%)
F   12.02 (-1.23%)
ACB   9.76 (-6.69%)
DIS   186.23 (-3.14%)
BA   226.86 (-0.74%)
NFLX   515.38 (-1.02%)
PFE   34.34 (-0.15%)
S&P 500   3,761.72 (-1.52%)
DOW   30,854.39 (-1.33%)
QQQ   304.08 (-1.64%)
AAPL   120.22 (-1.51%)
MSFT   226.51 (-0.46%)
FB   257.67 (+0.88%)
GOOGL   2,023.20 (+0.59%)
TSLA   610.76 (-6.50%)
AMZN   2,978.01 (-0.90%)
NVDA   495.31 (-3.30%)
BABA   230.98 (-2.24%)
CGC   30.99 (-6.77%)
GE   13.46 (+0.15%)
MU   84.19 (-5.52%)
NIO   38.90 (-6.33%)
AMD   78.13 (-3.38%)
T   28.91 (+0.66%)
F   12.02 (-1.23%)
ACB   9.76 (-6.69%)
DIS   186.23 (-3.14%)
BA   226.86 (-0.74%)
NFLX   515.38 (-1.02%)
PFE   34.34 (-0.15%)
S&P 500   3,761.72 (-1.52%)
DOW   30,854.39 (-1.33%)
QQQ   304.08 (-1.64%)
AAPL   120.22 (-1.51%)
MSFT   226.51 (-0.46%)
FB   257.67 (+0.88%)
GOOGL   2,023.20 (+0.59%)
TSLA   610.76 (-6.50%)
AMZN   2,978.01 (-0.90%)
NVDA   495.31 (-3.30%)
BABA   230.98 (-2.24%)
CGC   30.99 (-6.77%)
GE   13.46 (+0.15%)
MU   84.19 (-5.52%)
NIO   38.90 (-6.33%)
AMD   78.13 (-3.38%)
T   28.91 (+0.66%)
F   12.02 (-1.23%)
ACB   9.76 (-6.69%)
DIS   186.23 (-3.14%)
BA   226.86 (-0.74%)
NFLX   515.38 (-1.02%)
PFE   34.34 (-0.15%)
S&P 500   3,761.72 (-1.52%)
DOW   30,854.39 (-1.33%)
QQQ   304.08 (-1.64%)
AAPL   120.22 (-1.51%)
MSFT   226.51 (-0.46%)
FB   257.67 (+0.88%)
GOOGL   2,023.20 (+0.59%)
TSLA   610.76 (-6.50%)
AMZN   2,978.01 (-0.90%)
NVDA   495.31 (-3.30%)
BABA   230.98 (-2.24%)
CGC   30.99 (-6.77%)
GE   13.46 (+0.15%)
MU   84.19 (-5.52%)
NIO   38.90 (-6.33%)
AMD   78.13 (-3.38%)
T   28.91 (+0.66%)
F   12.02 (-1.23%)
ACB   9.76 (-6.69%)
DIS   186.23 (-3.14%)
BA   226.86 (-0.74%)
NFLX   515.38 (-1.02%)
PFE   34.34 (-0.15%)
Log in
CVE:NU

NeutriSci International Competitors

C$0.14
0.00 (0.00 %)
(As of 03/4/2021 12:43 PM ET)
Add
Compare
Today's Range
C$0.15
Now: C$0.15
C$0.15
50-Day Range
C$0.00
MA: C$0.17
C$0.29
52-Week Range
C$0.03
Now: C$0.15
C$0.35
Volume93,283 shs
Average Volume880,232 shs
Market CapitalizationC$22.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

NeutriSci International (CVE:NU) Vs. NDVA, CPH, HVT, EVE, SUGR, and AQS

Should you be buying NU stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to NeutriSci International, including Indiva (NDVA), Cipher Pharmaceuticals Inc. (CPH.TO) (CPH), Harvest One Cannabis (HVT), Eve & Co Incorporated (EVE), SugarBud Craft Growers Corp. (SUGR.V) (SUGR), and Aequus Pharmaceuticals (AQS).

NeutriSci International (CVE:NU) and Indiva (CVE:NDVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for NeutriSci International and Indiva, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeutriSci International0000N/A
Indiva00103.00

Indiva has a consensus price target of C$0.63, indicating a potential upside of 12.50%. Given Indiva's higher probable upside, analysts plainly believe Indiva is more favorable than NeutriSci International.

Valuation & Earnings

This table compares NeutriSci International and Indiva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15
IndivaC$7.92 million9.34C$-17,223,168.00C($0.13)-4.30

NeutriSci International has higher earnings, but lower revenue than Indiva. NeutriSci International is trading at a lower price-to-earnings ratio than Indiva, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeutriSci International and Indiva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeutriSci InternationalN/AN/AN/A
IndivaN/AN/AN/A

Summary

Indiva beats NeutriSci International on 4 of the 7 factors compared between the two stocks.

NeutriSci International (CVE:NU) and Cipher Pharmaceuticals Inc. (CPH.TO) (TSE:CPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for NeutriSci International and Cipher Pharmaceuticals Inc. (CPH.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeutriSci International0000N/A
Cipher Pharmaceuticals Inc. (CPH.TO)01002.00

Valuation & Earnings

This table compares NeutriSci International and Cipher Pharmaceuticals Inc. (CPH.TO)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15
Cipher Pharmaceuticals Inc. (CPH.TO)C$21.37 million1.08C$7.59 millionC$0.283.04

Cipher Pharmaceuticals Inc. (CPH.TO) has higher revenue and earnings than NeutriSci International. NeutriSci International is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals Inc. (CPH.TO), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeutriSci International and Cipher Pharmaceuticals Inc. (CPH.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeutriSci InternationalN/AN/AN/A
Cipher Pharmaceuticals Inc. (CPH.TO)N/AN/AN/A

Summary

Cipher Pharmaceuticals Inc. (CPH.TO) beats NeutriSci International on 4 of the 5 factors compared between the two stocks.

NeutriSci International (CVE:NU) and Harvest One Cannabis (CVE:HVT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Valuation & Earnings

This table compares NeutriSci International and Harvest One Cannabis' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15
Harvest One CannabisC$8.26 million4.16C$-78,288,756.00C($0.36)-0.44

NeutriSci International has higher earnings, but lower revenue than Harvest One Cannabis. NeutriSci International is trading at a lower price-to-earnings ratio than Harvest One Cannabis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for NeutriSci International and Harvest One Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NeutriSci International0000N/A
Harvest One Cannabis0000N/A

Profitability

This table compares NeutriSci International and Harvest One Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NeutriSci InternationalN/AN/AN/A
Harvest One CannabisN/AN/AN/A

Summary

NeutriSci International beats Harvest One Cannabis on 3 of the 5 factors compared between the two stocks.

Eve & Co Incorporated (CVE:EVE) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Earnings & Valuation

This table compares Eve & Co Incorporated and NeutriSci International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eve & Co IncorporatedC$2.84 million4.87C$-9,154,266.00C($0.32)-1.51
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15

NeutriSci International has lower revenue, but higher earnings than Eve & Co Incorporated. NeutriSci International is trading at a lower price-to-earnings ratio than Eve & Co Incorporated, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Eve & Co Incorporated and NeutriSci International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eve & Co Incorporated0000N/A
NeutriSci International0000N/A

Profitability

This table compares Eve & Co Incorporated and NeutriSci International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eve & Co IncorporatedN/AN/AN/A
NeutriSci InternationalN/AN/AN/A

Summary

NeutriSci International beats Eve & Co Incorporated on 3 of the 5 factors compared between the two stocks.

SugarBud Craft Growers Corp. (SUGR.V) (CVE:SUGR) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Profitability

This table compares SugarBud Craft Growers Corp. (SUGR.V) and NeutriSci International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SugarBud Craft Growers Corp. (SUGR.V)N/AN/AN/A
NeutriSci InternationalN/AN/AN/A

Earnings & Valuation

This table compares SugarBud Craft Growers Corp. (SUGR.V) and NeutriSci International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SugarBud Craft Growers Corp. (SUGR.V)C$66,906.00517.96C$-473,614,575.00C($1.03)-0.07
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15

NeutriSci International has higher revenue and earnings than SugarBud Craft Growers Corp. (SUGR.V). NeutriSci International is trading at a lower price-to-earnings ratio than SugarBud Craft Growers Corp. (SUGR.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for SugarBud Craft Growers Corp. (SUGR.V) and NeutriSci International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SugarBud Craft Growers Corp. (SUGR.V)0000N/A
NeutriSci International0000N/A

Summary

NeutriSci International beats SugarBud Craft Growers Corp. (SUGR.V) on 3 of the 5 factors compared between the two stocks.

Aequus Pharmaceuticals (CVE:AQS) and NeutriSci International (CVE:NU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aequus Pharmaceuticals and NeutriSci International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aequus Pharmaceuticals0000N/A
NeutriSci International0000N/A

Profitability

This table compares Aequus Pharmaceuticals and NeutriSci International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aequus PharmaceuticalsN/AN/AN/A
NeutriSci InternationalN/AN/AN/A

Valuation and Earnings

This table compares Aequus Pharmaceuticals and NeutriSci International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aequus PharmaceuticalsC$2.28 million11.31C$-2,462,174.00C($0.02)-10.45
NeutriSci InternationalC$69,626.00317.51C$-1,982,032.00C($0.01)-11.15

NeutriSci International has lower revenue, but higher earnings than Aequus Pharmaceuticals. NeutriSci International is trading at a lower price-to-earnings ratio than Aequus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

NeutriSci International beats Aequus Pharmaceuticals on 3 of the 5 factors compared between the two stocks.


NeutriSci International Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NDVA
Indiva
1.1$0.55flatC$27.54 millionC$7.92 million-4.30Gap Down
Cipher Pharmaceuticals Inc. (CPH.TO) logo
CPH
Cipher Pharmaceuticals Inc. (CPH.TO)
0.8$0.86flatC$23.80 millionC$21.37 million3.04
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.16flatC$21.51 millionC$8.26 million-0.44Gap Down
EVE
Eve & Co Incorporated
1.0$0.48flatC$21.32 millionC$2.84 million-1.51Gap Down
SUGR
SugarBud Craft Growers Corp. (SUGR.V)
0.7$0.08flatC$11.81 millionC$66,906.00-0.07Gap Up
AQS
Aequus Pharmaceuticals
0.9$0.23flatC$6.03 millionC$2.28 million-10.45
LBL
Lattice Biologics
0.5$0.05flatC$4.67 millionC$2.46 million-3.21News Coverage
Gap Up
THCX
(THCX.V)
0.6$5.30flatC$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.